The upregulation of Osteopontin mediates acquired resistance to EGFR-TKI in NSCLC through Integrin/FAK signaling Source: Virtual Congress 2020 – Biological mechanisms of lung cancer Year: 2020
Reduction of drug resistance through calcium control in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) resistant lung cancer cells Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer Year: 2020
Targeting of STAT3 and survivin with TG101209, a novel JAK2 inhibitor, enhances radiotherapy in lung cancer models Source: Annual Congress 2010 - New insights in the pathology of lung cancer Year: 2010
Overcome the EGFR-TKIs resistance with cucurbitacin BE compound by targeting STAT3, ERK1/2 and AKT Source: Annual Congress 2012 - New insights in the pathology of lung cancer Year: 2012
Blocking beta adrenergic signaling may be a target for overcoming EGFR TKI resistance. Source: International Congress 2018 – Lung cancer: from the bench to the bedside Year: 2018
EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice Source: Eur Respir J, 50 (2) 1700514; 10.1183/13993003.00514-2017 Year: 2017
Synergistic anti-tumor effects of vandetanib, an inhibitor of VEGFR and EGFR tyrosine kinase inhibitor, combined with cytotoxic agents in lung cancer cell lines Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010
Met amplification induces an aggressive phenotype in EGFR tyrosine kinase inhibitors resistant non-small-cell lung cancer Source: International Congress 2015 – New frontiers in biomedical research on thoracic tumours Year: 2015
Mutations of EGFR and k-ras genes and TK inhibitors. Are there differences between gefitinib and erlotinib? Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008
Potential therapeutic significance of CIK cells in gefitinib resistant NSCLC with EGFR mutations Source: Annual Congress 2011 - Progress in pathology of lung cancer Year: 2011
Use of multitarget tyrosine kinase inhibitors to attenuate platelet-derived growth factor signalling in lung disease Source: Eur Respir Rev, 26 (146) 170061; 10.1183/16000617.0061-2017 Year: 2017
TRAP1 downregulation could overcome gefitinib resistance in NSCLC via EMT reversal Source: International Congress 2018 – Lung cancer: novel molecular markers and mechanisms Year: 2018
Therapeutic strategy for EGFR driven NSCLC Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019
Simvastatin overcomes gefitinib resistance in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor via Akt/b-catenin signaling dependent down-regulation of survivin Source: Annual Congress 2013 –Basic research on lung cancer Year: 2013
The predictive value of circulating tumor DNA dynamics in plasma of EGFR-mutation-positive NSCLC patients on first line tyrosine kinase inhibitors Source: Virtual Congress 2021 – New clinical and biological developments in lung cancer Year: 2021
Salinomycin suppresses TGF-ß1-induced EMT by down-regulating MMP-2,9 via AMPK-SIRT1 pathway in a non-small cell lung cancer Source: International Congress 2017 – Basic research in lung cancer: a scientific potpourri from genetic alterations to immune cells Year: 2017
CREB signaling in KRAS-driven lung adenocarcinoma Source: ERS Lung Science Conference 2017 Year: 2017
Comparison of NSCLC patient groups with activated EGFR mutations treated with three different tyrosine-kinase inhibitors (TKI): Real-life data from the Czech Republic Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017
Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors Source: ERJ Open Res, 3 (3) 00092-2016; 10.1183/23120541.00092-2016 Year: 2017
Inhibition of VEGF blocks the activation of TGF-β1 through a PI3K/Akt signaling pathway in allergic airway disease of mice Source: Annual Congress 2007 - Current issues in airway physiology, pharmacology and monitoring Year: 2007